AUTO7 / Autolus - LARVOL DELTA

Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress (GlobeNewswire) - “AUTO7 in prostate cancer: Autolus plans to progress AUTO7 into the clinic in H1 2022...AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer term follow up of the fully enrolled r/r aALL cohort; AUTO1 - Currently enrolling Phase 1b/2 pivotal study (FELIX) in r/r adult ALL patients with data expected in 2022; Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in TRBC1+ Peripheral TCL, in 2021; Phase 1 trials are expected to be initiated in 2021 with AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma; First exploratory allogeneic program expected to enter the clinic in H1 2021.”

New P1 trial • New trial • P1 data • P1/2 data • Acute Lymphocytic Leukemia • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Multiple Myeloma • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prostate Cancer • Small Cell Lung Cancer